Pharma Retailer 111 Inc. Teams up With Lilly China
111 Inc. (Nasdaq: YI) announced Friday that it is launching a new diabetes patient management platform in cooperation with Lilly China.
The company said the platform's services include disease management, disease education, and patient support programs. They aim to help to enrich patients' knowledge of chronic disease management and to better help diabetic patients to self-manage from home.
"China has over 100 million diabetic patients, and it is crucial to help this large group of patients to manage their health effectively," Yu Gang, the co-founder and executive chairman of 111, said in the statement today.
He added, "Through our platform, we hope to provide patients with better access to information on diet, exercise, and medication specifically tailored to their individual needs, as well as a personalized management and treatment program that could help improve their own health. A step closer to the goals of Healthy China 2030."
Lilly China is the first multinational pharmaceutical company to join the platform, and it will leverage its expertise in the field of diabetes management and will also offer a variety of patient management and support programs, as reported in today's announcement.
On Monday, 111 announced that it has launched an overseas direct delivery service aiming to address the global shortage of personal protective equipment needed to combat the spread of Covid-19.
Based in Shanghai, 111 provides pharmaceutical products and healthcare services. The company sells through its e-commerce platform and indirectly through its offline pharmacy network. According to 111, it has partnerships with logistic and delivery giants including the United Parcel Service, Inc., (NYSE: UPS) and FedEx Corp. (NYSE: FDX)
The stock of 111 was trading at $7.66 intraday in New York, up 6 cents.